These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10073054)

  • 1. MMR vaccine coverage falls in the United Kingdom.
    Commun Dis Rep CDR Wkly; 1999 Jan; 9(5):37. PubMed ID: 10073054
    [No Abstract]   [Full Text] [Related]  

  • 2. Rates of first measles-mumps-rubella immunisation in Wales (UK).
    Thomas DR; Salmon RL; King J
    Lancet; 1998 Jun; 351(9120):1927. PubMed ID: 9654262
    [No Abstract]   [Full Text] [Related]  

  • 3. [The Communauté française' eradication plan for measles, mumps and rubella].
    Berghmans L; Swennen B; Dachy A; Reginster R; Thieffry P; Drumaux P
    Arch Belg; 1989; 47(1-4):8-10. PubMed ID: 2610579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACIP issues recommendations to eliminate measles, rubella and congenital rubella syndrome and to control mumps.
    Rose VL
    Am Fam Physician; 1998 Nov; 58(7):1682, 1685-6. PubMed ID: 9824963
    [No Abstract]   [Full Text] [Related]  

  • 5. Recommendations for using MMR vaccine in children allergic to eggs.
    Khakoo GA; Lack G
    BMJ; 2000 Apr; 320(7239):929-32. PubMed ID: 10787255
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measles, measles vaccination, and Crohn's disease. Second immunisation has not affected incidence in England.
    Miller E; Waight P
    BMJ; 1998 Jun; 316(7146):1745. PubMed ID: 9614036
    [No Abstract]   [Full Text] [Related]  

  • 8. MMR vaccine coverage falls after adverse publicity.
    Commun Dis Rep CDR Wkly; 1998 Jan; 8(5):41, 44. PubMed ID: 9505460
    [No Abstract]   [Full Text] [Related]  

  • 9. Moving the second dose of measles-mumps-rubella vaccine to school entry: implications for control of rubella.
    Heath TC; Burgess MA; Forrest JM
    Commun Dis Intell; 1998 Aug; 22(8):157-8. PubMed ID: 9735550
    [No Abstract]   [Full Text] [Related]  

  • 10. MMR vaccination, Crohn's disease and autism: a real or imagined "stomach ache/headache?".
    Passwell JH
    Isr Med Assoc J; 1999 Nov; 1(3):176-7. PubMed ID: 10731330
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunise Australia program: measles control campaign.
    Commun Dis Intell; 1998 Aug; 22(8):156. PubMed ID: 9735549
    [No Abstract]   [Full Text] [Related]  

  • 12. MMR immunisation coverage in Christchurch. Christchurch Immunisation Coordination Committee.
    Ford RP; Bell DW; Slade B; McCormack SP
    N Z Med J; 1998 Aug; 111(1071):301. PubMed ID: 9760956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign.
    D'Souza RM; Campbell-Lloyd S; Isaacs D; Gold M; Burgess M; Turnbull F; O'Brien E
    Commun Dis Intell; 2000 Feb; 24(2):27-33. PubMed ID: 10758692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response.
    Halperin SA; McGrath P; Smith B; Houston T
    J Pediatr; 2000 Jun; 136(6):789-94. PubMed ID: 10839878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles control.
    Durham G
    N Z Med J; 1997 Jul; 110(1047):259. PubMed ID: 9251716
    [No Abstract]   [Full Text] [Related]  

  • 16. [Measles. A viral illness with risk of permanent damage].
    Butenandt O; Weiss M
    MMW Fortschr Med; 1999 Sep; 141(37):30-2. PubMed ID: 10897970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Need for measles revaccination.
    John TJ
    Indian Pediatr; 1998 Aug; 35(8):789-91. PubMed ID: 10216577
    [No Abstract]   [Full Text] [Related]  

  • 19. MMR vaccination and autism 1998. Those giving MMR vaccine had no input into editorial.
    Kiln MR
    BMJ; 1998 Jun; 316(7147):1824. PubMed ID: 9652942
    [No Abstract]   [Full Text] [Related]  

  • 20. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.